

This is the peer reviewed version of the following article:

Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome / Ferraro, Diana; Galli, Veronica; Simone, Anna Maria; Bedin, Roberta; Vitetta, Francesca; Merelli, Elisa; Nichelli, Paolo Frigio; Sola, Patrizia. - In: JOURNAL OF NEUROVIROLOGY. - ISSN 1355-0284. - 23:2(2017), pp. 329-334. [10.1007/s13365-016-0493-9]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

05/01/2026 18:23

## Dear Author

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style.
- Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

### Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

<http://dx.doi.org/10.1007/s13365-016-0493-9>

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to:

<http://www.link.springer.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

## Metadata of the article that will be visualized in OnlineFirst

Please note: Images will appear in color online but will be printed in black and white.

1	Article Title	<b>Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome</b>	
2	Article Sub- Title		
3	Article Copyright - Year	<b>Journal of NeuroVirology, Inc. 2016 (This will be the copyright line in the final PDF)</b>	
4	Journal Name	Journal of NeuroVirology	
5	Corresponding Author	Family Name	<b>Ferraro</b>
6		Particle	
7		Given Name	<b>Diana</b>
8		Suffix	
9		Organization	AUSL Modena
10		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
11	Author	Address	Via Pietro Giardini, 1355, Modena 41126
12		Organization	University of Modena and Reggio Emilia
13		Division	Department of Biomedical Metabolic and Neurosciences
14		Address	Via Pietro Giardini, 1355, Modena 41126
15		e-mail	perdiana@tin.it
16		Family Name	<b>Galli</b>
17	Author	Particle	
18		Given Name	<b>Veronica</b>
19		Suffix	
20		Organization	University of Modena and Reggio Emilia
21		Division	Neuroimmunology Laboratory, Department of Biomedical, Metabolic and Neurosciences
22		Address	Via Pietro Giardini, 1355, Modena 41126
23	Author	e-mail	
24		Family Name	<b>Simone</b>
25		Particle	
26		Given Name	<b>Anna Maria</b>
27		Suffix	

28		Organization	AUSL Modena
29		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
30		Address	Via Pietro Giardini, 1355, Modena 41126
31		Organization	University of Modena and Reggio Emilia
32		Division	Department of Biomedical Metabolic and Neurosciences
33		Address	Via Pietro Giardini, 1355, Modena 41126
34		e-mail	
35	Author	Family Name	<b>Bedin</b>
36		Particle	
37		Given Name	<b>Roberta</b>
38		Suffix	
39		Organization	University of Modena and Reggio Emilia
40		Division	Neuroimmunology Laboratory, Department of Biomedical, Metabolic and Neurosciences
41		Address	Via Pietro Giardini, 1355, Modena 41126
42		e-mail	
43	Author	Family Name	<b>Vitetta</b>
44		Particle	
45		Given Name	<b>Francesca</b>
46		Suffix	
47		Organization	AUSL Modena
48		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
49		Address	Via Pietro Giardini, 1355, Modena 41126
50		e-mail	
51	Author	Family Name	<b>Merelli</b>
52		Particle	
53		Given Name	<b>Elisa</b>
54		Suffix	
55		Organization	AUSL Modena
56		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
57		Address	Via Pietro Giardini, 1355, Modena 41126
58		e-mail	
59	Author	Family Name	<b>Nichelli</b>
60		Particle	
61		Given Name	<b>Paolo Frigio</b>

62		Suffix	
63		Organization	AUSL Modena
64		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
65		Address	Via Pietro Giardini, 1355, Modena 41126
66		Organization	University of Modena and Reggio Emilia
67		Division	Department of Biomedical Metabolic and Neurosciences
68		Address	Via Pietro Giardini, 1355, Modena 41126
69		e-mail	
70		Family Name	<b>Sola</b>
71		Particle	
72		Given Name	<b>Patrizia</b>
73		Suffix	
74	Author	Organization	AUSL Modena
75		Division	Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense
76		Address	Via Pietro Giardini, 1355, Modena 41126
77		e-mail	
78		Received	7 January 2016
79	Schedule	Revised	7 October 2016
80		Accepted	20 October 2016
81	Abstract	Epstein-Barr virus (EBV) has been implicated in multiple sclerosis (MS) pathogenesis. We aimed to assess the frequency of EBV-specific IgG and IgM oligoclonal bands (OCB) in cerebrospinal fluid (CSF) of 50 patients with clinically isolated syndrome (CIS) and in 27 controls with Guillain-Barré syndrome (GBS). Furthermore, we assessed correlations between the presence of OCB and CIS patients' CSF, MRI, and clinical variables. There was no difference in the proportion of CIS and GB patients with positivity for anti-EBV-specific IgG/IgM OCB. There were no correlations between OCB and analyzed variables, nor were they predictive of a higher disability at 3 years.	
82	Keywords separated by ' - '	Epstein-Barr virus - Clinically isolated syndrome - Multiple sclerosis - Oligoclonal IgG bands - Oligoclonal IgM bands	
83	Foot note information		

Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome

Diana Ferraro<sup>1,2</sup> · Veronica Galli<sup>3</sup> · Anna Maria Simone<sup>1,2</sup> · Roberta Bedin<sup>3</sup> · Francesca Vitetta<sup>1</sup> · Elisa Merelli<sup>1</sup> · Paolo Frigio Nichelli<sup>1,2</sup> · Patrizia Sola<sup>1</sup>

Received: 7 January 2016 / Revised: 7 October 2016 / Accepted: 20 October 2016  
© Journal of NeuroVirology, Inc. 2016

**Abstract** Epstein-Barr virus (EBV) has been implicated in multiple sclerosis (MS) pathogenesis. We aimed to assess the frequency of EBV-specific IgG and IgM oligoclonal bands (OCB) in cerebrospinal fluid (CSF) of 50 patients with clinically isolated syndrome (CIS) and in 27 controls with Guillain-Barré syndrome (GBS). Furthermore, we assessed correlations between the presence of OCB and CIS patients' CSF, MRI, and clinical variables. There was no difference in the proportion of CIS and GB patients with positivity for anti-EBV-specific IgG/IgM OCB. There were no correlations between OCB and analyzed variables, nor were they predictive of a higher disability at 3 years.

**Keywords** Epstein-Barr virus · Clinically isolated syndrome · Multiple sclerosis · Oligoclonal IgG bands · Oligoclonal IgM bands

Introduction

Epidemiological data, including a seroprevalence >99% in multiple sclerosis (MS) patients (compared to 94% in

controls) (Ascherio and Munger 2007) and a higher risk of MS in subjects with a history of infectious mononucleosis (Handel et al. 2010), indicates that EBV may play a role in MS pathogenesis. The high infection prevalence in MS patients has suggested that it may be a prerequisite for the development of MS, although pathogenetic mechanisms are still unclear and hypotheses include promotion of autoimmunity by EBV-infected autoreactive B cells, bystander damage related to anti-EBV responses, and cross-reactivity between EBV and central nervous system (CNS) antigens (Holmøy, Kvale, and Vartdal 2004; Lang et al. 2002; Lünemann et al. 2008).

A debated issue is whether EBV represents an antigenic target for antibody production within the CNS.

Castellazzi et al. (Castellazzi et al. 2014) recently reported, among other findings, that local synthesis of cerebrospinal fluid (CSF) specific IgG oligoclonal bands (OCB) directed against Epstein-Barr virus (EBV) occurred in 21% of 100 patients with relapsing-remitting multiple sclerosis (RRMS), and that they had a low affinity in all patients. Authors concluded that the EBV-specific intrathecal oligoclonal IgG production is probably unrelated to the cause of the disease, but may occur in a subset of MS patients as part of a humoral polyreactivity directed against many different pathogens.

We hereby report on similar findings in a group of 50 patients with clinically isolated syndrome (CIS). We furthermore report results on the frequency of CSF-restricted EBV-specific IgM OCB in the CIS cohort, on the correlations between the presence of anti-EBV-specific IgG and IgM bands and CSF, MRI and clinical variables (including disability and the risk of conversion to clinically definite MS within the subsequent 3 years), and on the frequency of EBV-specific IgG and IgM OCB in a control group of 27 patients with Guillain-Barré syndrome (GBS).

✉ Diana Ferraro  
perdiana@tin.it

<sup>1</sup> Neurology Unit, Nuovo Ospedale Civile S. Agostino Estense, AUSL Modena, Via Pietro Giardini, 1355, 41126 Modena, Italy  
<sup>2</sup> Department of Biomedical Metabolic and Neurosciences, University of Modena and Reggio Emilia, Via Pietro Giardini, 1355, 41126 Modena, Italy  
<sup>3</sup> Neuroimmunology Laboratory, Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Via Pietro Giardini, 1355, 41126 Modena, Italy

## 65    **Methods and materials**

### 66    **Patients**

67    Of 201 consecutive patients with a first demyelinating event  
 68    (CIS) seen at our center, whose CSF and serum had been  
 69    stored at  $-80^{\circ}\text{C}$  after collection, we selected those patients  
 70    ( $n = 50$ ) who proved positive for both CSF-restricted IgG  
 71    OCB and CSF IgM OCB (the latter were CSF-restricted in  
 72    40 patients and present as a “mirror pattern”, i.e., identical  
 73    bands in CSF and serum, in 10 patients). Furthermore, of 38  
 74    patients diagnosed with GBS, we selected 27, who showed a  
 75    CSF IgG mirror pattern, as controls.

### 76    **Data collection**

77    Of all CIS patients, we recorded demographic (sex, age at  
 78    onset), clinical (symptoms at onset, EDSS at onset, and clin-  
 79    ical recovery), MRI (presence and number of brain and spinal  
 80    cord MRI lesions, presence and number of gadolinium-  
 81    enhancing lesions on MRI, and presence of spinal/  
 82    infratentorial lesions), and routine CSF data collected at onset  
 83    (CSF proteins, cell count, Link's IgG Index, presence of IgG  
 84    OCB and CSF/serum albumin quotient, indicating a blood-  
 85    brain barrier dysfunction if value  $>6.5 \times 10^3$ ), as well as  
 86    follow-up data including the occurrence of relapses and dis-  
 87    ability status (EDSS) (Kurtzke 1983) in the subsequent  
 88    3 years.

### 89    **Laboratory procedures**

#### 90    *Cerebrospinal fluid and serum sampling*

91    Laboratory procedures were carried out on CSF, and serum  
 92    samples from each patient, which, at the time of the diagnostic  
 93    spinal tap, had been centrifuged at 3000 rpm for 10 min and  
 94    stored in cryovial tubes at  $-80^{\circ}\text{C}$  within 2 h from collection.

95    CSF and serum samples were analyzed for the presence of  
 96    IgM OCB by means of agarose gel isoelectric focusing (IEF)  
 97    followed by immunoblotting with polyclonal specific anti-  
 98    human IgM antibodies (Dako), according to the method pro-  
 99    posed by Villar et al. (L. M. Villar et al. 2001), with some  
 100    modifications (Ferraro et al. 2015). We obtained the approval  
 101    of the Modena Ethics Committee (protocol nr. 116/09).

#### 102    *EBV antigen-specific immunoblotting*

103    EBV-specific OCB were investigated by antigen-specific im-  
 104    munoblotting as reported by Castellazzi et al. (Castellazzi  
 105    et al. 2014), using the same mixture of antigens (Genway  
 106    Biotech, Inc. San Diego, CA, USA, a P3H3 extract crude viral  
 107    lysate containing a high concentration of EBV antigens, in-  
 108    cluding VCA, EBNA, early antigen diffuse, and early antigen

restricted). However, we did not use a commercial kit to carry  
 out IEF. For IEF, we used agarose gel, polyvinylidene fluoride  
 membrane, rabbit anti-human IgG (primary antibody), poly-  
 clonal swine anti-rabbit Ig/AP (secondary antibody conjugat-  
 ed to alkaline phosphatase) (Dako Cytomation), and nitro blue  
 tetrazolium and bromo-chloroindoleyl phosphate as dyes.

The presence of CSF IgM OCB and of EBV-specific IgG  
 and IgM OCB (at least two) was blindly assessed by two  
 independent neurologists (DF and PS) and by a biologist  
 (RB) in case of discrepancies.

### Statistical methods

We calculated absolute frequencies and percentages for cate-  
 gorical variables and mean  $\pm$  standard deviation and median  
 for continuous variables. Mann-Whitney's test and Fisher's  
 exact test were used to explore differences between groups.  
 We used logistic regression to assess the relationship between  
 anti-EBV-specific OCB status and the risk of disability or of a  
 relapse (with subsequent diagnosis of clinically definite MS-  
 CDMS) at 1 and 3 years in CIS patients.

## Results

### CIS and GBS patient characteristics

CIS patients' demographic, clinical, MRI, and CSF character-  
 istics are shown in Table 1.

CIS patients with positivity for IgM OCB, and thus select-  
 ed for this study, do not differ from IgM OCB-negative pa-  
 tients of the initial CIS cohort ( $n = 201$ ) with respect to base-  
 line variables, except for a higher number of gadolinium-  
 enhancing lesions on baseline MRI in IgM OCB-positive pa-  
 tients ( $1.1$  vs  $0.5$ ,  $p = 0.01$ ).

GBS patients' demographic and CSF characteristics are  
 shown in Table 2.

### Frequency of EBV-specific IgG and IgM in CIS and GBS patients

In CIS, CSF-restricted EBV-specific IgG OCB (see Fig. 1)  
 were present in 14 (28%) of patients and a EBV-specific IgG  
 OCB in a mirror pattern in three (11%), while CSF-restricted  
 EBV-specific IgM OCB (Fig. 2) were present in three (6%).

In GBS, EBV-specific IgG OCB (mirror pattern) were pres-  
 ent in six (22 %) of patients, while EBV-specific IgM OCB  
 were present in three (16 %).

There were no statistically significant differences in the  
 proportion of CIS and GB patients with positivity for EBV-  
 specific IgG OCB or IgM OCB ( $p = 0.78$  and  $p = 0.34$ ,  
 respectively).



Q2


t1.1	<b>Table 1</b> Baseline demographic, clinical, MRI, and CSF characteristics of CIS patients (nr = 50)	
t1.2	Sex M/F	14/36
t1.3	Age at onset, years*	33 ± 9
t1.4	Symptoms at onset	
t1.5	ON, <i>n</i> (%)	16 (32)
	Sensory, <i>n</i> (%)	12 (24)
	Motor/sensory motor, <i>n</i> (%)	6 (12)
	Brainstem/cerebellum, <i>n</i> (%)	13 (26)
	Other, <i>n</i> (%)	3 (6)
t1.6	Spinal onset, yes/no	18/32
t1.7	EDSS at onset*	2.3 ± 1
t1.8	Complete recovery, <i>n</i> (%)	41 (82)
t1.9	Baseline brain MRI	
t1.10	0 lesions, <i>n</i> (%)	4 (8)
	1–2 lesions, <i>n</i> (%)	7 (14)
	>2lesions, <i>n</i> (%)	39 (78)
	Presence of infratentorial lesions, <i>n</i> (%)	25 (50)
	Presence of CE, <i>n</i> (%)	26 (54)
t1.11	Baseline spinal cord MRI (available in 26 patients)	
t1.12	Positive (at least one lesion), <i>n</i> (%)	20 (77)
t1.13	Total CSF protein* (normal value 15–45 mg/dl)	38.5 ± 12
	Patients with elevated CSF protein, <i>n</i> (%)	13 (28)
t1.14	Cells* (normal value <4/mm3)	7.2 ± 8
	Patients with elevated CSF cells, <i>n</i> (%)	30 (63)
t1.15	CSF/serum albumin* (normal value <6.5)	4.1 ± 1.3
	Patients with elevated CSF serum/albumin, <i>n</i> (%)	3 (6)
t1.16	IgG index* (normal value <0.7)	1.2 ± 0.5
	Patients with elevated IgG index, <i>n</i> (%)	45 (92)

ON optic neuritis, CE contrast enhancement  
\*Values expressed as mean ± SD

153 **Correlations between EBV-specific IgG/IgM OCB**  
154 **and clinical, MRI, and CSF parameters in CIS patients**  
  
155 There were no differences in baseline clinical, MRI, and CSF  
156 variables between EBV-specific IgG OCB positive and nega-  
157 tive patients, except for a higher mean number of CSF cells in  
158 EBV-specific IgG OCB-negative patients; there were no dif-  
159 ferences in follow-up data (Table 3). EBV-specific IgM OCB


t2.1	<b>Table 2</b> Demographic and CSF characteristics of GBS patients (nr = 27)	
t2.2	Sex M/F	18/9
t2.3	Age at onset, years*	54 ± 17
t2.4	Total CSF protein* (normal value 15–45 mg/dl)	91 ± 49
	Patients with elevated CSF protein, <i>n</i> (%)	23 (85)
t2.5	Cells* (normal value <4/mm3)	32 ± 124
	Patients with elevated CSF cells, <i>n</i> (%)	7 (26)
t2.6	CSF/serum albumin* (normal value <6.5)	14.1 ± 9.7
	Patients with elevated CSF serum/albumin, <i>n</i> (%)	23 (85)

\*Values expressed as mean ± SD



**Fig. 1** EBV-specific IgG OCB in a CIS patient. Identical amounts of serum (S) and cerebrospinal fluid (CSF) IgG were isoelectrically focused and transferred to uncoated membrane (left) or membrane coated with EBV viral antigens (right). The figure shows a CIS patient with positivity for CSF-restricted IgG OCB (left) and for EBV-specific IgG OCB (right)

positive patients did not differ from EBV-specific IgM OCB- 160  
negative patients with regard to baseline and follow-up data 161  
(data not shown). 162



**Fig. 2** EBV-specific IgM OCB in a CIS patient. The figure shows the CSF and serum of one CIS patient with positivity for CSF-restricted IgM OCB (left) and EBV-specific IgM OCB (right)



**Table 3** Demographic, clinical, MRI, CSF, and follow-up data of EBV-specific IgG OCB positive and negative CIS patients. Significant results in bold.

Variable	Presence of EBV-specific CSF-restricted OCB (14 patients)	Absence of EBV-specific CSF-restricted OCB (36 patients)	<i>p</i> value
Sex M/F	1/13	13/23	0.07
Age at onset, years*	32 ± 8	33 ± 10	0.74
Spinal onset, yes/no	5/9	13/23	1
EDSS at onset*	1.9 ± 0.6	2.5 ± 1.1	<b>0.03</b>
Complete recovery, yes/no	13/1	8/28	0.21
Baseline brain MRI			
At least one lesion, yes/no	13/1	33/3	0.7
Presence of infratentorial lesions, yes/no	7/7	18/18	1
Presence of CE, yes/no	6/7	20/15	0.36
Baseline spinal cord MRI			
Positive (at least one lesion), yes/no	6/7	20/15	0.4
Total CSF protein* (normal value 15–45 mg/dl)	35 ± 9	40 ± 13	0.34
Elevated CSF protein yes/no, yes/no	3/10	10/23	0.46
Cells* (normal value <4/mm <sup>3</sup> )	3.9 ± 2.6	8.4 ± 8.8	<b>0.04</b>
Elevated CSF cells yes/no, yes/no	6/7	24/11	0.14
CSF/serum albumin* (normal value <6.5)	3.8 ± 1.1	4.2 ± 1.4	0.21
Elevated CSF serum/albumin, yes/no	1/13	2/32	0.65
IgG index* (normal value <0.7)	1.1 ± 0.5	1.2 ± 0.6	0.97
Elevated IgG index yes/no, yes/no	11/3	34/1	0.07
CDMS diagnosis at 1 year, yes/no	7/7	13/23	0.3
CDMS diagnosis at 3 years, yes/no	11/3	22/14	0.2
EDSS at 3 years*	1.1 ± 1.2	1.5 ± 1.3	0.42
EDSS annual progression*	0.19 ± 0.35	0.25 ± 0.37	0.52

CE contrast enhancement

\*Values expressed as mean ± SD

Patients with EBV-specific IgG and IgM OCB did not have a higher risk of conversion to CDMS at 1 or 3 years or of a higher disability at 3 years at logistic regression analysis (data not shown).

## Discussion

In the present study, we found no differences in the proportion of CIS and GB patients with positivity for anti-EBV-specific IgG or IgM OCB. EBV-specific CSF OCB were reported in a variable proportion of MS patients (Cepok et al. 2005; Franciotta et al. 2011; Rand et al. 2000; Virtanen et al. 2014), though, in part, they were not CSF-restricted but present in both serum and CSF (Franciotta et al. 2011; Rand et al. 2000; Virtanen et al. 2014).

With regard to EBV-specific intrathecal IgG synthesis, as measured by CSF-to-serum antibody indices, some studies found no evidence for increased frequency of intrathecal antibody production against EBV in MS patients compared to controls (Jafari et al. 2010), or compared to the response to other viruses (Pohl et al. 2010), while another found such

evidence only early in the disease course, i.e., within 1 year from onset (Jaquière et al. 2010).

The present study, carried out early in the disease course, at the time of the first demyelinating event (median interval between clinical onset and spinal tap, 2 weeks; range, 0–5 months), shows that the intrathecal synthesis of EBV-specific IgG OCB is present only in a proportion of patients with CIS and the frequency of EBV-specific IgG OCB in the CSF of CIS patients does not differ from that of control subjects with GBS. Clearly, CSF anti-EBV OCB in CIS patients differ from those found in GBS patients, since they are CSF-restricted in CIS patients, and present in “a mirror pattern” (with identical bands in serum, indicating passive transfer from serum to CSF) in GBS patients. This is, however, what we would expect in case of an intrathecal antibody production against a target antigen within the CNS in CIS patients, as opposed to a systemic response against a target antigen in the peripheral nervous system in GBS patients.

In order to increase the probability of finding an intrathecal EBV-specific immune response, we also sought to examine whether an intrathecal production of EBV-specific IgM OCB may be present in CIS patients, since a recent study (Beltrán

et al. 2014) showed that there were no clonal overlaps between the IgG and the IgM CSF repertoires, suggesting that IgM- and IgG-producing B cells independently enter the intrathecal compartment, and that they further mature and expand independently of each other in the CSF without intrathecal isotype switching from IgM to IgG. Furthermore, the majority of CSF IgM OCB (in particular those directed against lipids and which are thought to be secreted by CD5+ B cells) are persistent and do not represent a transient primary immune response (L. Villar et al. 2008). IgM OCB are present in approximately 40% of MS patients and 20% of patients with CIS (Boscá et al. 2010; Ferraro et al. 2013). To our knowledge, however, this is the first study assessing the presence of EBV-specific IgM OCB in MS patients. Only a very small proportion of patients, however, showed a positivity for EBV-specific IgM OCB (6%), and, again, the frequency did not differ from that of EBV-specific IgM OCB in control subjects with GBS.

Finally, data on high serum levels of anti-EBNA-1 or anti-EBV-VCA IgG increasing the risk of developing MS in CIS patients (Lünemann et al. 2010) and correlating with MRI activity (Farrell et al. 2009; Lünemann et al. 2010), disability (Lünemann et al. 2010) and brain atrophy (Zivadinov et al. 2009) in MS patients, prompted us to evaluate whether CIS patients with positivity for EBV-specific IgG/IgM OCB showed different clinical/CSF/MRI parameters or if they had a worse prognosis in terms of conversion to MS and disability during a 3-year follow-up, but our data did not support this hypothesis.

Conclusion

There was no difference in the proportion of CIS and GB patients with positivity for CSF anti-EBV-specific IgG or IgM OCB. Furthermore, there were no correlations between EBV-specific IgG/IgM OCB and CIS patients' clinical, MRI, and CSF parameters, nor did we find evidence for a prognostic role of EBV-specific IgG/IgM OCB in CIS patients.

Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

We obtained the approval of the Modena Ethics Committee (protocol nr. 116/09).

References

Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. *Ann Neurol* 61:288–299

Beltrán E, Obermeier B, Moser M, Coret F, Simó-Castelló M, Boscá I, Pérez-Miralles F, Villar LM, Senel M, Tumani H, Hohlfeld R, Casanova B, Dommair K (2014) Intrathecal somatic hypermutation

of IgM in multiple sclerosis and neuroinflammation. *Brain* 137: 2703–2714

Boscá I, Magraner MJ, Coret F, Alvarez-Cermeño JC, Simó-Castelló M, Villar LM, Casanova B (2010) The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. *J Neuroimmunol* 226:143–146

Castellazzi M, Contini C, Tamborino C, Fasolo F, Roversi G, Seraceni S, Rizzo R, Baldi E, Tola M, Bellini T, Granieri E, Fainardi E (2014) Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. *J Neuroinflammation* 11:188

Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büsow K, Sommer N, Hemmer B (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. *J Clin Invest* 115:1352–1360

Farrell R, Antony D, Wall GR, Clark D, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G (2009) Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. *Neurology* 73:32–38

Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, Morselli F, Filippini MM, Nichelli PF, Sola P (2015) Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. *J Neuroimmunol* 283:64–69

Ferraro D, Simone AM, Bedin R, Galli V, Vitetta F, Federzoni L, D'Amico R, Merelli E, Nichelli PF, Sola P (2013) Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. *J Neuroimmunol* 257:76–81

Franciotta D, Di Stefano AL, Jarius S, Zardini E, Tavazzi E, Ballerini C, Marchioni E, Bergamaschi R, Ceroni M (2011) Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. *J Neuroimmunol* 230:160–163

Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PLoS One* 5. doi:10.1371/journal.pone.0012496

Holmøy T, Kvale EØ, Vartdal F (2004) Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. *J Neurovirol* 10:278–283

Jafari N, van Nierop GP, Verjans GM, Osterhaus AD, Middeldorp JM, Hintzen RQ (2010) No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. *J Clin Virol* 49:26–31

Jaquière E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, Du Pasquier R (2010) Intrathecal immune responses to EBV in early MS. *Eur J Immunol* 40:878–887

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 33:1444–1452

Lang H, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis. *Nat Immunol* 3: 940–943

Lünemann JD, Jelčić I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Münz C (2008) EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. *J Exp Med* 205:1763–1773

Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M (2010) Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. *Ann Neurol* 67:159–169

Pohl D, Rostasy K, Jacobi C, Lange P, Nau R, Krone B, Hanefeld F (2010) Intrathecal antibody production against Epstein-Barr and

318	other neurotropic viruses in pediatric and adult onset multiple sclerosis. <i>J Neurol</i> 257:212–216	for the detection of oligoclonal IgM bands. <i>J Immunol Methods</i> 258:151–155	329
319			330
320	Rand KH, Houck H, Denslow ND, Heilman KM (2000) Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in	Virtanen JO, Wohler J, Fenton K, Reich DS, Jacobson S (2014) Oligoclonal bands in multiple sclerosis reactive against two herpes-	331
321	patients with multiple sclerosis. <i>J Neurol Sci</i> 173:32–39	viruses and association with magnetic resonance imaging findings. <i>Mult Scler</i> 20:27–34	332
322			333
323	Villar L, García-Barragán N, Espiño M, Roldán E, Sádaba M, Gómez-Rial J, González-Porqué P, Alvarez-Cermeño J (2008) Influence of oligoclonal IgM specificity in multiple sclerosis disease course. <i>Mult Scler</i> 14:183–187	Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M (2009) Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. <i>J Neurol Neurosurg Psychiatry</i> 80:620–625	334
324			335
325	Villar LM, González-Porqué P, Masjuán J, Alvarez-Cermeño JC, Bootello A, Keir G (2001) A sensitive and reproducible method		336
326			337
327			338
328			339
340			

UNCORRECTED PROOF

## AUTHOR QUERIES

**AUTHOR PLEASE ANSWER ALL QUERIES.**

- Q1. Please check if author names and affiliations are captured correctly.
- Q2. Please check if Tables 1, 2, and 3 are presented correctly.
- Q3. An ethics statement is necessary for studies involving human or animal subjects. Relevant to this, a related statement was copied from the text and placed under "Compliance with ethical standards." Please check if the statement is appropriate and amend as deemed necessary.

UNCORRECTED PROOF